Search Results - "Galego, Andrea"
-
1
Isoagglutinin Titers in ABO-Incompatible Kidney Transplant
Published in Transplantation proceedings (01-11-2021)“…A decrease in the isoagglutinin titer <1:8 is usually required for ABO-incompatible (ABOi) transplantation and the presence of high predesensitization titers…”
Get full text
Journal Article -
2
ABO incompatible live donor renal transplant. Study of 48 patients after desensitization
Published in Nefrología (01-11-2019)“…Until recently, ABO-incompatible living donor kidney transplantation was regarded as an absolute contraindication. However, this kind of kidney transplantation…”
Get full text
Journal Article -
3
Retrospective Multicenter Study of Extracorporeal Photopheresis in Steroid-Refractory Acute and Chronic Graft-versus-Host Disease
Published in Biology of blood and marrow transplantation (01-04-2020)“…•Photopheresis is an effective treatment for refractory graft-versus-host disease (GVHD).•Overall response to treatment is the most important variable for…”
Get full text
Journal Article -
4
Trasplante renal de donante vivo ABO incompatible. Estudio de 48 pacientes tras desensibilización
Published in Nefrología (01-11-2019)“…El trasplante renal de donante vivo ABO incompatible era considerado una contraindicación absoluta. Desde hace años, se realiza con buenos resultados. Nuestro…”
Get full text
Journal Article -
5
ABO-incompatible living-donor kidney transplantation: Study of 48 patients after desensitisation
Published in Nefrología (01-11-2019)“…BACKGROUNDABO-incompatible living-donor kidney transplantation was regarded as an absolute contraindication. However, it has been carried out for years with…”
Get full text
Journal Article -
6
Multicentric, Retrospective Study of Extracorporeal Photopheresis, Off-Line System, in Corticosteroid Refractory Acute and Chronic Graft-Versus-Host Disease
Published in Blood (29-11-2018)“…BACKGROUND Graft-versus-host disease (GvHD) remains an important cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation,…”
Get full text
Journal Article -
7
Progression-Free Survival at 24 Months (PFS24) and Complete Response at 30 Months (CR30) from Autologous Stem Cell Transplantation (ASCT) Should be Used As Surrogates for OS in Follicular Lymphoma (FL) Patients
Published in Blood (03-12-2015)“…Introduction: At present, determining OS (Overall Survival) remains the gold standard in clinical trial endpoints which evaluate the role of ASCT in FL…”
Get full text
Journal Article -
8
Progression‐free survival at 2 years post‐autologous transplant: a surrogate end point for overall survival in follicular lymphoma
Published in Cancer medicine (Malden, MA) (01-12-2017)“…Overall survival (OS) is the gold‐standard end point for studies evaluating autologous stem cell transplantation (ASCT) in follicular lymphoma (FL), but…”
Get full text
Journal Article -
9
Intensive (2+5) Or Semi-Intensive (FLUGA) Chemotherapy For Patients With Acute Myeloid Leukemia Who Are 70 Years Of Age Or Older
Published in Blood (15-11-2013)“…Intensive chemotherapy in patients with acute myeloid leukemia (AML) who are 70 years of age or older leads to an overall survival (OS) lower than 30% at one…”
Get full text
Journal Article -
10
Successful treatment of pure red cell aplasia with high-dose dexamethasone after ABO-incompatible allogeneic hematopoietic stem cell transplantation
Published in Hematology/oncology and stem cell therapy (01-03-2018)“…The literature reports an incidence of Pure Red Cell Aplasia (PRCA) ranging from 6-30% of all cases of ABO-incompatible HSCT. Although most patients resolve…”
Get full text
Journal Article